Comment on: Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials

doi:10.1038/s41443-026-01333-5

Comment on: Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials

Journal: International journal of impotence research (Q2)
Published: 23 July 2026
Study design: Systematic review / meta-analysis of RCTs
Evidence level: Level 1, High (CEBM 1a)
Authors: Amin Sharifan
PMID: 42493582
DOI: 10.1038/s41443-026-01333-5

Why clinicians should know about it

Picked for Urology (top studies of the week, 26 July 2026): Testosterone therapy cardiovascular and prostate cancer risk meta-analysis

View on PubMed Full text at the publisher Open in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.